Rapid immune reconstitution of SCID-X1 canines after G-CSF/AMD3100 mobilization and in vivo gene therapy

Abstract

<p id="d13975227e298"> <div class="list"> <a class="named-anchor" id="d13975227e300"> <!-- named anchor --> </a> <ul class="so-custom-list"> <li id="d13975227e301"> <div class="so-custom-list-content so-ol"> <p class="first" id="d13975227e302">IV delivery of FV vector using the phosphoglycerate kinase promoter outperforms EF1α-containing vector in the canine SCID-X1 model. </p> </div> </li> <li id="d13975227e304"> <div class="so-custom-list-content so-ol"> <p class="first" id="d13975227e305">G-CSF/AMD3100 mobilization before in vivo FV vector delivery improves kinetics and clonal diversity of lymphocyte reconstitution. </p> </div> </li> </ul> </div> </p><p class="first" id="d13975227e310">Hematopoietic stem-cell gene therapy is a promising treatment of X-linked severe combined immunodeficiency disease (SCID-X1), but currently, it requires recipient conditioning, extensive cell manipulation, and sophisticated facilities. With these limitations in mind, we explored a simpler therapeutic approach to SCID-X1 treatment by direct IV administration of foamy virus (FV) vectors in the canine model. FV vectors were used because they have a favorable integration site profile and are resistant to serum inactivation. Here, we show improved efficacy of our in vivo gene therapy platform by mobilization with granulocyte colony-stimulating factor (G-CSF) and AMD3100 before injection of an optimized FV vector incorporating the human phosphoglycerate kinase enhancerless promoter. G-CSF/AMD3100 mobilization before FV vector delivery accelerated kinetics of CD3 ⁺ lymphocyte recovery, promoted thymopoiesis, and increased immune clonal diversity. Gene-corrected T lymphocytes exhibited a normal CD4:CD8 ratio and a broad T-cell receptor repertoire and showed restored γC-dependent signaling function. Treated animals showed normal primary and secondary antibody responses to bacteriophage immunization and evidence for immunoglobulin class switching. These results demonstrate safety and efficacy of an accessible, portable, and translatable platform with no conditioning regimen for the treatment of SCID-X1 and other genetic diseases. </p><p id="d13975227e318"> <div class="fig panel" id="absf1"> <a class="named-anchor" id="absf1"> <!-- named anchor --> </a> <div class="figure-container so-text-align-c"> <img alt="" class="figure" src="/document_file/158373d0-bc1c-4212-9c93-7b813dd9abab/PubMedCentral/image/advances016451absf1"/> </div> <div class="panel-content"/> </div> </p>